Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Maximillian Diehn"'
Autor:
Divij Mathew, Melina E. Marmarelis, Caitlin Foley, Joshua M. Bauml, Darwin Ye, Reem Ghinnagow, Shin Foong Ngiow, Max Klapholz, Soyeong Jun, Zhaojun Zhang, Robert Zorc, Maximillian Diehn, Wei-Ting Hwang, Nancy R. Zhang, Corey J. Langer, E. John Wherry, Andy J. Minn
Persistent inflammation including type-one interferon (IFN-I) can cause immunosuppression. We show that delayed administration of the JAK1 inhibitor itacitinib after anti-PD1 improves immune function and anti-tumor response in mice, and results in hi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6ea5cedeb9c0d7fb0eeda841e15e7df
https://doi.org/10.1101/2022.11.05.22281973
https://doi.org/10.1101/2022.11.05.22281973
Autor:
Matthew P. Deek, Kim Van der Eecken, Philip Sutera, Rebecca A. Deek, Valérie Fonteyne, Adrianna A. Mendes, Karel Decaestecker, Ana Ponce Kiess, Nicolaas Lumen, Ryan Phillips, Aurélie De Bruycker, Mark Mishra, Zaker Rana, Jason Molitoris, Bieke Lambert, Louke Delrue, Hailun Wang, Kathryn Lowe, Sofie Verbeke, Jo Van Dorpe, Renée Bultijnck, Geert Villeirs, Kathia De Man, Filip Ameye, Daniel Y. Song, Theodore DeWeese, Channing J. Paller, Felix Y. Feng, Alexander Wyatt, Kenneth J. Pienta, Maximillian Diehn, Soren M. Bentzen, Steven Joniau, Friedl Vanhaverbeke, Gert De Meerleer, Emmanuel S. Antonarakis, Tamara L. Lotan, Alejandro Berlin, Shankar Siva, Piet Ost, Phuoc T. Tran
Publikováno v:
JOURNAL OF CLINICAL ONCOLOGY
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Tr